We’re enjoying our new office/lab space and being in the heart of the action of Cambridge amongst our biotech peers, pharma companies, and other life science partners. The best part? We’re torn between the cutting-edge lab features like our new BD FACSymphony flow cytometer and the natural light throughout the space. #Biotechnology #LifeSciences
Larkspur Biosciences
Biotechnology Research
Watertown, MA 1,528 followers
Building the next precision immunotherapies to outsmart cancer.
About us
Larkspur Biosciences is building the next precision immunotherapies to outsmart cancer. Larkspur’s approach targets the unique ways that tumors hijack the immune system by developing precision immunotherapies for molecularly defined patient populations in order to overcome these bottlenecks that allow the tumor to subvert the immune system. We are advancing our first-in-class programs to outsmart the tumor and enable robust and sustained immune responses in colorectal cancer (CRC) and beyond. LarkX, our target discovery platform, leverages tumor genetics and immune phenotypes from patient-derived data to fuel its pipeline and offers the opportunities to address multiple types of cancer. We believe that transformational discoveries are found at the interface between disciplines. With a proven track record of drug discovery and development, our team is passionate about solving hard problems and driven to deliver new medicines to cancer patients with significant unmet needs. At Larkspur, we grow together, building a culture that highly values joy, trust, and courage.
- Website
-
https://larkspur.bio/
External link for Larkspur Biosciences
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Watertown, MA
- Type
- Privately Held
- Founded
- 2020
- Specialties
- Oncology, Immunotherapy, and Precision Medicine
Locations
-
Primary
Get directions
480 Arsenal Way
Suite 125
Watertown, MA 02472, US
Employees at Larkspur Biosciences
Updates
-
June is Cancer Immunotherapy Awareness Month, and we’re honoring the significant impact that breakthroughs in immunotherapy have had on the lives of cancer survivors and individuals fighting cancer. At Larkspur, we are building on advances in cancer treatment, including immunotherapy, to develop new options for patients who do not respond to current targeted therapies and immunotherapies. Our approach — a new wave of cancer therapy — identifies cancer-intrinsic factors that drive immune escape, and our small molecule programs target these tumor “bottlenecks” as potential new treatment options. More here: https://bit.ly/3wVdaIi #Immunotherapy #CancerCare #CancerResearch #Innovation
-
-
Larkspur’s Catherine Sabatos-Peyton, PhD, & Emily Corse, PhD, are in Chicago for #ASCO24. They’re looking forward to connecting with peers, like our SAB member Antoni Ribas, MD, PhD, and discussing new advances in cancer treatment. #ASCO2024
-
-
We're thrilled to be in our new lab space in Cambridge and one of the first tenants of One Canal by Breakthrough Properties. Larkspur occupies 12,500 square feet of the office-to-lab conversion, which is an increase of 50% more space than our previous location. Check out the Boston Business Journal on One Canal: https://bit.ly/3QSctWD Stay tuned for interior photos! #Biotechnology #Research #LifeScience
-
We are proud to be pioneering a new wave in cancer therapy that stops immune evasion where it starts — in the tumor. More on our science: https://lnkd.in/djNMgCjs #CancerResearch #NCRM24 #Cancer
-
-
Don’t miss our new data on the targeted protein degradation of the lipid kinase PIP4K2C, a novel cancer target considered part of the 'dark kinome.' Check out our #AACR24 poster, “Degradation of PIP4K2C by novel bivalent functional degrader LRK-A induces tumor regression in CRC” at https://lnkd.in/eyEMeJRr #CancerResearch #Oncology #ColorectalCancer
-
-
Our CEO, Catherine Sabatos-Peyton, recently shared her insights on advanced AI and biophysical modeling with Outsourcing-Pharma as part of its Vox Pop Pharma series. She cites Larkspur’s LarkX platform enabling targeted protein degradation of PIP4K2C and the discovery of orthogonal cancer-intrinsic mechanisms of immune evasion as examples of recent advancements underscoring the promising potential of machine learning in drug discovery. Read more: https://bit.ly/3xHUfk7 #cancer #AI #AIinHealthcare
-
-
We're thrilled to share that The Termeer Foundation Foundation has named our CEO, Catherine Sabatos-Peyton, as a 2024 Termeer Fellow. Congrats to all of the 2024 Termeer Fellows! #Healthcare #Innovation
We are thrilled to announce the Class of 2024 Termeer Fellows - a group of 15 visionary leaders poised to transform patient care through groundbreaking discovery. Each Fellow embodies the spirit of innovation and patient-centered care that is reflected in the Termeer Foundation’s values. This cohort of CEOs are at the forefront of tackling some of society’s most pressing health challenges. Under the Termeer Fellowship, they will receive values-driven leadership programming, mentorship, and access to a network of industry leaders, all dedicated to accelerating their journey towards creating impactful solutions for patients worldwide. The Termeer Fellowship Program is entering its seventh year, and continues to be committed to empowering leaders with the tools, resources, and community support they need to succeed. Join us in congratulating the 2024 Termeer Fellows and learn more about their groundbreaking work. Hanne Callewaert, CEO and Cofounder of AstriVax Dr. Tinashe Chandauka, CEO and Cofounder of Nandi Life Sciences LLC Ying Kai Chan, CEO and Cofounder of of Cirrus Therapeutics Aaron Edwards, CEO and Cofounder of KiraGen Bio Floris Engelhardt, CEO and Cofounder of Kano Therapeutics Manuel Marina Breysse, CEO and Cofounder of Idoven Natalie Winblade Nairn, Cofounder, CEO, and CSO of Cyclera Therapeutics Nabanita Nawar, PhD, CEO and Cofounder of HDAX Therapeutics Richard Novak, CEO and Cofounder of Unravel Biosciences Catherine Sabatos-Peyton, CEO of Larkspur Biosciences Shardule Shah, PhD, MBA, CEO and Cofounder of Lime Therapeutics Carla Spina PhD, CEO and Cofounder of Noa Therapeutics Theresa Tribble, CEO of Droplet Biosciences, Inc Fernando Vieira, CEO and CSO at the ALS Therapy Development Institute Dan Jing Wu, CEO and Cofounder, VivArt-X Discover more about our 2024 Fellows and how The Termeer Foundation empowers leaders who are bringing life-changing treatments to patients: https://lnkd.in/ef5izqGY. #TermeerFoundation #HealthcareInnovation #RareDisease #Biotech #PatientCare #GlobalCollaboration #Massachusetts #Netherlands #biotechnology #lifescience #bio #health #pharma #peopleempoweringcures #connectionsempoweringcures #leadershipmatters #healthcare #mentorship #science #mentor #leader #ceo #lifescience #stem #bio #TermeerFellows
-
-
Tomorrow at #AACR24: don’t miss our presentation on LRK-A, our first-in-class, lead investigational therapy targeting the dark lipid kinase PIP4K2C. Data show the potential of targeted PIP4K2C degradation as a treatment for colorectal cancer. More here: https://bit.ly/3VFTqCf #CancerResearch #Cancer #Oncology #ColorectalCancer
-
-
Attending #AACR24? Larkspur’s Eva d'Hennezel will present new preclinical research on LRK-A, a first-in-class PIP4K2C protein degrader. The data demonstrate that LRK-A drives monotherapy anti-tumor activity, including complete tumor regressions, in primary human tumor samples and a mouse model of colorectal cancer. bit.ly/3VFTqCf #CancerResearch #Cancer #Oncology American Association for Cancer Research
-